Gail J. Roboz, MD, discusses recent therapeutics developments in the treatment of patients with acute myeloid leukemia.
Gail J. Roboz, MD, professor of medicine, and director of the Clinical and Translational Leukemia Program, Weill Medical College of Cornell University, discusses recent therapeutics developments in the treatment of patients with acute myeloid leukemia (AML).
For decades, very few advances were made in the treatment of this patient population, despite multiple clinical trials, according to Roboz. However, this has changed, with 9 new approved approaches in just the past few years, Roboz says. The approvals span a variety of different types of therapy, including cytotoxic chemotherapy, as well as several targeted therapies; these options have collectively changed the treatment landscape of AML, Roboz notes.
Many treatments, both as single agents and in combination, have been adopted as new standards of care. However, there is still work to be done to find curative treatments for this patient population, Roboz concludes.